GE's Clarient Gains IP Rights from Insight Genetics to Develop PCR-based ALK Test | GenomeWeb

Originally published June 1.

With the aim of inking companion diagnostic partnerships with pharma companies investigating drugs inhibiting the anaplastic lymphoma kinase, GE Healthcare announced plans this week to develop a PCR-based ALK-mutation test.

Clarient Diagnostic Services, a GE subsidiary, has garnered a worldwide, non-exclusive license from Insight Genetics enabling it to develop a genetic test that gauges ALK expression.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece appearing in Newsday likens familial DNA search to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.

Startup companies are taking on personalized medicine, CNET reports.